Oppenheimer raised the firm’s price target on Wave Life Sciences (WVE) to $32 from $24 and keeps an Outperform rating on the shares following the interim results for WVE-007 and the follow-through last week. To the firm, the most important takeaways from the highly encouraging update are the clean safety profile and the clear translatability from human genetics and preclinical work to clinical results for WVE-007. Oppenheimer is optimistic that the data will further improve with longer follow-up/higher doses, and in subsequent studies.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WVE:
- Wave Life Sciences price target raised to $50 from $36 at Truist
- Wave Life Sciences price target raised to $37 from $19 at B. Riley
- Wedbush raises price target on Wave Life Sciences, adds to Best Ideas List
- Wedbush adds Wave Life Sciences to Best Ideas List, ups target to $33
- Wave Life Sciences falls -17.2%